This article has been updated from a previous version to retract information originally provided by Abbott in a statement.

NEW YORK (GenomeWeb) – Abbott today announced that it has signed an exclusive licensing agreement with the Institut Curie for a biomarker for bladder cancer.

Genetic mutations in FGFR3 can be used for early detection, disease monitoring, and predicting patient outcomes in both urine and tissue-based testing. FGFR3 gene mutations are seen in about 70 percent of low-grade and 15 to 20 percent of high-grade bladder cancer cases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.